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Human peritoneal mesotheial cells synthesize interleukin-6: Induction
by IL.113 and TNFa. Recent studies have demonstrated increased levels
of IL-6 in the peritoneal cavity during CAPD peritonitis. The current
investigation was initiated (i) to examine the human peritoneal mesothe-
hal cell (HPMC) as a possible source of this secreted IL-6 and (ii) to
characterize the released product and examine its regulation by other
cytokines. Unstimulated HPMC under growth arrested conditions
released IL-6 in a time dependent manner. After 24-hour HPMC IL-6
release (mean SEM, N = 13) (expressed as pg cell protein) was 1.67
0.33. Stimulation of HPMC with IL-1f3 or TNFa resulted in a time
(increasing up to 48 hr) and dose dependent IL-6 generation. After 24
hours the levels induced by IL-1/3 and TNFa (both at 1000 pg/mi) were
(mean SEM, N = 13) 19.08 2.98 and 6.62 1.72, respectively.
Stimulation with combinations of IL-1/3 and TNFa resulted in additive
increases in IL-6 release. This release could be inhibited by co-
incubation with anti-IL-113 and/or anti-TNFa antibodies. The level of
released HPMC IL-6 measured by immunometric assay (ELISA) cor-
related directly with that detected in the 7TD1 IL-6 bioassay (r = 0.63;
P < 0.001). Western blot analysis of concentrated HPMC supernatants
using specific anti-IL-6 antibody demonstrated immunoreactive bands
at 23 and 28 Kd following IL-1f3 or TNFa treatment. PCR amplification
of reverse transcribed HPMC mRNA using specific IL-6 primers
demonstrated a single 465 base pair transcript, the expression of which
was enhanced in a time dependent manner following treatment of
HPMC with either IL-113 or TNFa. These data demonstrate for the first
time that HPMC synthesize IL-6 and that its release can be regulated as
a result of increased expression of specific mRNA and de novo protein
synthesis by other cytokines. HPMC derived IL-6 might contribute
directly to the cytokine network regulating intraperitoneal inflammatory
responses associated with bacterial peritonitis.
Increasing evidence suggests that the mesothelial cell lining,
the peritoneal cavity, plays a more than passive role during
inflammatory events therein. In this respect we and others have
demonstrated that it is a major source of prostaglandins in the
peritoneal cavity [1—3]. In addition activated peritoneal macro-
phages can directly elevate mesothelial cell arachidonic acid
metabolism at least partly as a result of their secretion of
interleukin-lp (IL-113) and tumor necrosis factor a (TNFa) [4].
Macrophages form the highest proportion of resident phago-
cytic cells in the sterile pentoneal cavity and examination of
dialysis effluent from patients during the beginning of a perito-
nitis episode, clearly indicates that this cell type forms the first
line of defense against invading microorganisms [51. These cells
are capable of providing the initial signals for subsequent
recruitment of neutrophils via secretion of chemotactic mole-
cules such as leukotrienes and interleukin-8 [6—8]. The PMØ
isolated from CAPD patients appear to behave as elicited or
primed cells rather than as a resident macrophage population [6,
7]. This increases the potential for the intraperitoneal genera-
tion of pro-inflammatory substances, such as lipid mediators
and cytokines, which may be capable of activating other cell
populations [9, 10].
The role of the mesothelial cell during the initiation of
peritoneal inflammation is poorly defined, and its contribution
to the cytokine network has yet to be elucidated.
IL-6 is a polypeptide mediator produced by a variety of cell
types, including T-cells, fibroblasts, epithelial and endothelial
cells. Increased local levels of IL-6 have been demonstrated in
many inflammatory conditions [11, 12] and exert a variety of
systemic effects [13]. Actions include the induction of B-cell
differentiation and immunoglobulin production and stimulation
of acute phase protein synthesis by the liver [14, 15].
It has recently been demonstrated that dialysis effluent,
collected during episodes of peritonitis, contains very large
amounts of IL-6 bioactivity which is assumed to be derived
mainly from invading inflammatory cells [16].
The present investigation set out to examine HPMC as the
possible source of intraperitoneal IL-6 secretion, to character-
ize any released activity and examine its regulation by other
cytokines (IL-1f3 and TNFa). We demonstrate that cultured
human mesothelial cells express specific mRNA and release
significant quantities of immunoreactive and bioactive IL-6.
The mesothelium may be a potential source of this molecule
during peritoneal inflammation.
Methods
All chemicals, unless otherwise stated, were obtained from
the Sigma Chemical Company (Poole, Dorset, UK). Recombi-
nant human IL-lp was a gilt from Dr. D. Borasehi, Sclavo
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Research Centre (Siena, Italy). Its specific activity was 2.5 x
io U/mg as assessed in the EL-4 l6/CTLL bioassay. Human
TNFa was from BASF AG (Ludwigshafen, Germany). Its
specific activity was 8 x iO U/mg protein (as assessed in a 48
hr L929 bioassay in the absence of actinomycin D). All cytokine
preparations were batched and stored at —70°C and freshly
thawed for each experiment. Endotoxin contamination of re-
combinant material was <0.7 pg/fig protein as assessed by
limulus amoebocyte lysate assay (Kabi Vitrum, Stockholm,
Sweden). Goat anti-human IL-1$ and goat anti-human IL-6
antibodies were a gift from The National Institute of Biological
Standards and Control (NIBSC), Potters Bar (Herts, UK) and
monoclonal anti-TNFa antibody (mono Ab 195) was provided
by BASF AG.
Isolation and culture of human peritoneal mesothelial cells
Human peritoneal mesothelial cells (HPMC), obtained from
the omental tissue of consenting patients undergoing elective
abdominal surgery, were isolated and characterized essentially
as described previously. The cells cultured were pure mesothe-
hal cells as assessed by their uniform cobblestone appearance at
confluence, by the presence of surface microvihli, by the lack of
staining for factor VIII related antigen and the uniform positive
staining for cytokeratins 8 and 18 [3]. The presence of contam-
inating macrophages was excluded following examination of Pc
receptor expression (using a red cell rosetting assay [3]) and Ia
(class II MHC) antigen immunostaining, both of which were
negative in all mesothehial cell cultures examined. Cells were
maintained in Ham's F12 medium (CM) (ICN Biomedicals Ltd,
High Wycombe, Bucks, UK) supplemented with penicillin (100
U/nil), streptomycin (100 mg/mi), L-glutamine (2 mM) (Gibco
BRL Life Technologies Ltd, Uxbridge, UK), transferrin (5
g/ml), insulin (5 g/ml), hydrocortisone (0.4 sg/ml) (all from
Sigma) and 10% vollvol fetal calf serum (FCS) (ICN Biomedi-
cals Ltd). Cells were passaged using trypsin : EDTA: glucose
(0.125% wt/vol:0.01% wt/vol :0.1% wt/vol). All data presented
are from experiments performed with cells from the second
passage which had previously been growth arrested. There was
no difference in reactivity of mesothehial cell cultures irrespec-
tive of passage number, cells were used from the second
passage and not later to maximize cell numbers but to avoid
using cultures containing senescent cells [3].
Establishment of growth arrested HPMC
HPMC were grown to confluence in rat tail collagen treated
[17] 250 ml flasks or in multi-well plates and then transferred to
CM containing 0.1% volivol FCS (rest medium) for 48 hours
prior to stimulation. Previous experiments had demonstrated
that at this time point the cells were maintained in a viable (as
assessed by the lack of LDH release) but nonproliferative state
(data not shown). Under these conditions the cells could be
maintained for up to 96 hours without any significant loss of
viability.
Western blotting
Synthesis and molecular weight characterization of secreted
IL-6 was examined by Western blot analysis using specific
sheep anti-human IL-6 (NIBSC). Ten to 40 d of lOx concen-
trated (Centricon 3 micro-concentrators, Amicon Ltd, Stone-
house, UK) culture supernatants from growth arrested control
and cytokine stimulated HPMC and recombinant IL-6 (10 zg)
were subjected to electrophoresis in 1.5 mm thick 5 to 20%
gradient SDS polyacrylamide gels (mini-Protean II, BioRad
Laboratories Ltd, Hemel Hempstead, UK). After electrophore-
sis the gels were equilibrated in blot buffer (7.81 m Tris, 60
mM glycine 20% vol/vol methanol, pH 8.3) and transblotted for
four hours at 0°C at 200 mA constant current on to pre-wetted
nitrocellulose (Immobilon P; Milhipore UK Ltd, Watford, UK).
The blotted membrane was placed in blocking buffer (PBS
containing 1% wt/vol bovine serum albumin (BSA; ICN Bio-
medicals Ltd) and 0.1% vol/vol Tween 20 overnight at 4°C. The
blots were washed (x 6) with PBS and incubated overnight at
4°C with the primary antibody (1: 1500) dissolved in PBS,
Tween 20 (0.1% vollvol) BSA (1% wt/vol), and then incubated
(60 mm at room temperature) with alkaline phosphatase conju-
gated rabbit anti-goat IgG (1: 5000), dissolved in Tris-buffered
saline containing 0.1% vol/vol BSA.
The blot was washed again (x4 with PBS-Tween 20) and
developed following incubation with 50 ml of substrate buffer
(0.1 M Tris-HC1 pH 9.5, 0.1 M NaCl and 5 mM MgC12)
containing nitroblue tetrazolium (0.33 mg/ml), 5-bromo-4-
chloro-3 indolyl phosphate (BCIP) (170 tg/ml). The blots were
dried overnight and photographed. The molecular weights of
developed bands were compared to those of prestained SDS-
PAGE standards (low range; Bio-Rad Laboratories Ltd, Hemel
Hemstead, UK).
RNA isolation, reverse transcription and PCR amplification
HPMC were grown to confluence in 24 well plates and growth
arrested as previously described. Total cellular RNA was
extracted from both control and cytokine treated HPMC fol-
lowing lysis with 4 M guanidine isothiocyanate and centrifuga-
tion through 5.7 M cesium chloride in 0.1 M EDTA [18]. As a
result of the limited amount of material available IL-6 mRNA
expression was examined using PCR of reverse transcribed
HPMC mRNA.
Two micrograms of total RNA sediment was dissolved in 5 p1
water containing 75 ng oligo dT (Pharmacia Biosystems Ltd,
Milton Keynes, UK) by heating to 65°C. At room temperature
4 p1 of 3 x reverse transcription buffer (United States Biochem-
icals, Cleveland, Ohio, USA) containing 0.125 U RNAase
blocker (Stratagene Ltd, Cambridge, UK) was added and mixed
thoroughly. Reverse transcription was performed after addition
of 3.5 p1 of substrate enzyme mix (18 nmol dNTP's (Pharmacia
Biosystems Ltd) and 5 U reverse transcriptase (Stratagene Ltd)
at 37°C for one hour. The reaction mixture was diluted to 100 p1
with water and stored at —20°C.
PCR amplification was performed in a total volume of 25 p1(5
p1 of reverse transcription product and 20 1.d of master mix) 0.6
U Taq polymerase (Perkin-Elmer Ltd, Beaconsfield, UK) 20
LM of each primer, 20 nM dNTP's (Gene Amp-kit; Perkin-
Elmer Ltd). The reaction mix was overlayed with 20 p1 mineral
oil. Various amplification cycles (20 to 35) were carried out
starting with denaturation at 94°C for one minute, followed by
primer annealing at 60°C for one minute, and extension at 72°C
for one minute. Extension time was incremented by 5 sec/cycle.
The terminal product was kept at 4°C.
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Table 1. Amplification primers
Product
Gene Oligonucleotide sequence size Reference
Cyclophillin 3'-CATCTGCACTGCCAAGACTG
CTGCAATCCAGCTAGGCATG-5'
326 [19]
IL-6 3'-TACATCCCTCGACGGATCTC
GCTACATTTGCCGAAGAGCC-5'
465 [20]
a-Actin 3'-TCTCCACAACCCTCTGCACC
GGAGCAATGATCTTGATCTT-5'
234 [29]
Analysis of PCR products
One-tenth of the PCR reaction product was separated by flat
bed electrophoresis in 1.5% wt/vol agarose gels (BioRad Lab-
oratories Ltd) stained with ethidium bromide and photo-
graphed. The negatives were scanned using a densitometer
(Model 620 video densitometer, Bio-Rad Laboratories Ltd) and
the density of the bands compared to those of the housekeeping
gene.
Oligonucleotide synthesis
Oligonucleotides were automatically synthesized (Applied
Biosystems, USA). Matrix bound oligonucleotides were split
and de-protected by incubation in NH4OH (33% vol/vol) at 55°C
overnight, lyophilized and used directly. The sequences of the
amplification primers are in Table I.
Induction of IL-6 production by HPMC
HPMC monolayers were grown to confluency in collagen
coated 24-well plates (Falcon; Becton-Dickinson UK Ltd,
Oxford, UK), and growth arrested for 48 hours in CM contain-
ing 0.1% vollvol FCS as previously described, washed x4 with
rest medium, and then incubated at 37°C in the presence or
absence of the appropriate stimulus. At specific time intervals,
HPMC supernatants were removed, centrifuged at 12,000 x g
and then stored at —70°C until assayed. At the end of the
incubation period the cells were washed with PBS (pH 7.3)
(Dulbecco; Oxoid Ltd, Basingstoke, UK) and the cellular
protein solubilized with 0.1 N NaOH. Total cellular protein was
estimated in these supernatants using the modified Bradford
method [21]. Repeated cell counts revealed that 1 g of cellular
protein was equivalent to 3.76 0.56 x i0 cells (N = 5). All
data for IL-6 production are expressed as pg/pjg of cellular
protein.
Cytokine synthesis measurements
Synthesised IL-6 was measured in the culture supernatants of
control and simulated (growth arrested) HPMC by specific
sandwich-ELISA. Briefly, 96-well microtiter plates were coated
with affinity purified rabbit anti-mouse IgG (Dakopats, Ham-
burg, FRG) in PBS for one hour at room temperature, the plates
were washed >3 with PBS Tween 20 0,05% vol/vol (PBS-
Tween) and incubated with mouse monoclonal anti-human IL-6
antibody (primary antibody) (Serva, Heidelburg, Germany),
recombinant IL-6 standard (British Biotechnology Ltd, Oxford,
UK) or test supernatants. The plates were washed x3 with
PBS-Tween and incubated with biotinylated goat anti-human
IL-6 (R&D Systems, Minneapolis, Minnesota, USA) for 30
minutes at 30°C. The detection system consisted of Streptavi-
din-peroxidase (Calbiochem, Frankfurt, Germany) and 3,3'5,5'-
tetramethyl benzidine (Fluka, Buchs, Switzerland). Once the
color had developed the optical density was assessed at 450 and
630 nm in a microtiter plate reader (MR 5000; Dynatech
Laboratories Ltd, Billingshurst, Sussex, UK). The IL-6 con-
centration in the samples was calculated by comparison with
standard concentrations ranging from 20 to 2000 pg/ml. The
sensitivity of the assay was 20 pg/ml. There was no apparent
cross reactivity in this assay with IL-la, IL-1f3, TNFa, TNFI3,
IL-2 or IL-4 (British Biotechnology Ltd.) when these were
added to blanks in concentrations up to 50 ng/ml. HPMC
supernatants containing IL-6, as measured by ELISA, were
subsequently subjected to bioactivity measurement using the
7TD1 bioassay as previously described [221.
Statistical analysis
All statistical analyses were performed by using the Wilcoxon
signed rank test for paired non-parametric data, a P value of
less than 0.05 being considered as significant. All data are
presented as mean (±sEM).
Results
Synthesis of IL-6 by HPMC
Unstimulated non-proliferating HPMC released IL-6 in a time
dependent manner which was significantly above background
by 12 hours and reached a plateau between 24 and 48 hours.
After 24 hours the mean (± SEM) release of IL-6 was 1.40 0.97
pg/pg cellular protein (N = 5; Fig. 1 A and B).
Cytokine induction of HPMC IL-6
Stimulation of non-proliferating HPMC with IL-113 or TNFa
enhanced the time dependent generation of IL-6. This release
became significant above background levels after a lag phase of
three hours with both IL-1/3 (1000 pg/mI) (z = 2.203; P < 0.01)
and TNFa (1000 pg/ml) (z = 2.203; P < 0.01) and continued to
rise over the whole time course studied.
The release of IL-6 in response to IL-1f3 and TNFa was also
dose dependent. After 24 hours significant release above back-
ground levels was achieved with doses of IL-1/3 above 5 pg/ml
(z = 1.96, P < 0.05) and with TNFa doses above 10 pg/mI (z =
2.66;P < 0.01; Fig. 2). Maximal generation of HPMC IL-6 was
stimulated with an IL-1f3 dose of 1000 pg/ml when the release
was 19.08 0.33 pgljsg, N = 13 cellular protein, which was
11-fold above background levels (z = 2.66; P < 0.01). The
release in response to TNFa continued to rise over the whole
dose range tested; at a dose of TNFa of 5000 pg/mI the released
IL-6 levels had reached 7.84 1.78 pg/pg, N = 13, fivefold
above background levels (z = 2.023; P < 0.01).
Conzbined cytokine stimulation
Stimulation of non-proliferating HPMC with combinations of
IL-i f3 and TNFa resulted in the generation of IL-6 above the
levels generated by each cytokine alone. The level of release,
however, was not significantly different from the additive
values of the two cytokines when each was used alone (data not
shown). Peak stimulation of IL-6 in these experiments was
obtained at the highest combination of cytokine concentrations
tested (IL-i$, 5000 pg/mI + TNFa 50 pg/mI) when the 24 hour
release was 21.52 8.16 pg/pjg cell protein (mean SEM, N
isi.1.i
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Fig. 2. Dose effect of IL-i 13 (•; 0.1 to 5000pg/mI) and TNFx (; 0.1
to 5000pg/mi) on the 24 hour generation of IL-6 from HPMC. The data
presented are the (mean sEM) IL-6 release expressed as pg/zg cell
protein, from 13 separate experiments with HPMC prepared from
separate omental specimens. * represents a statistically significant
difference (P < 0.05) compared to the control unstimulated IL-6 release
value.
Western blot analysis
Western blot analysis of concentrated (x 10) HPMC superna-
tants, using specific polyclonal anti-IL-6 antibody, revealed the
expression of immunoreactive bands at approximately 23 and
28 Kd following stimulation of HPMC with either IL-i /3 or
TNFa (Fig. 4).
PCR amplification of HPMC mRNA
5). In these experiments the levels of IL-6 generated in response
to individual stimulation with the highest concentrations of
IL-l/3 (5000 pg/mi) or TNFa (5000 pg/mi) tested were 17.32
5.99 and 7.84 1.78 pg4tg cellular protein (N = 5), respec-
tively.
IL-6 bioactivity
The supernatants from non-proliferating unstimulated and
cytokine stimulated HPMC were assessed for IL-6 bioactivity
in the 7TD1 proliferation assay. These estimations correlated
directly with the data obtained with the same samples measured
in the IL-6 ELISA (R2 = 0.631, P < 0.01, N = 50).
Antibody inhibition studies
The specificity of the IL-1J3 and TNFa stimulation of HPMC
IL-6 was confirmed in antibody inhibition experiments with
PCR amplification of reverse transcribed HPMC mRNA,
using specific IL-6 primers resulted in the generation of a single
465 base pair IL-6 transcript. Prior stimulation of HPMC with
IL-1f3 (Fig. SA) or TNFa (Fig. SB) resulted in a time dependent
induction of specific IL-6 transcript as assessed densitometri-
cally (Fig. SC), when compared to 24-hour unstimulated control
HPMC mRNA levels (lane 1). In separate experiments HPMC
were exposed to either control medium or IL-113 (1000 pg/mi) or
TNFa (1000 pg/ml) for six hours at 37°C. At this time point IL-6
specific mRNA was demonstrable in both unstimulated and
cytokine treated HPMC. In cytokine treated HPMC the levels
of IL-6 specific mRNA were, however, markedly increased as
assessed densitometrically. Under the same conditions the level
of the housekeeping gene a-actin mRNA remained unaltered
(Fig. 6A and B).
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Fig. 1. A. Time dependent generation of IL-6 from unstimulated HPMC (--•--), or from HPMC stimulated with IL-i 13110 (--D--) and 1000 (—--)
pg/mi]. The data presented are the (mean SCM) IL-6 release expressed as pg/pg cell protein, from five separate experiments with HPMC prepared
from separate omental specimens. B. Time dependent generation of IL-6 from unstimulated HPMC (--•--), or HPMC stimulated with TNFa [10
(--Lx--) and 1000 (—A—) pg/mlj. The data presented are the (mean SCM) IL-6 release expressed as pg/pg cell protein, from five separate experiments
with HPMC prepared from separate omental specimens. * represents a statistically significant difference (P < 0.05) compared to unstimulated IL-6
release at the same time point.
25 1 * specific anti-cytokine antibodies (Fig. 3 A and B). Co-incuba-
— tion of HPMC with IL- 1/3 or TNFa in the presence of a fixed
dose (that calculated to inhibit 100 pg/mi of the respective
cytokine) of polyclonal anti-IL-f3 antibody or monoclonal anti-
TNFa antibody resulted in inhibition of IL-6 generation at all
cytokine doses tested. At an IL-1f3 concentration of 100 pg/mi,
IL-6 synthesis was reduced by a mean (±5EM, N = 3) of 83.08
10% (Fig. 4A). At a TNFa concentration of 100 pg/mi IL-6
release was reduced by 84.7 9.3% (mean SEM, N = 3; Fig.
— 3B).
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20.
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Fig. 3. Antibody inhibition of cytokineinduced HPMC IL-6 release. A. Dose effect of IL- 1/3 (; 0.1 to 1000 pg/mi) on the release of IL-6 from
HPMC in the absence and in the presence of a neutralizing dose (sufficient to inhibit 100 pg/mI IL-i/3) of polyclonal sheep anti-human IL-1/3 (s).
Data represent the (mean sEM) five separate experiments with HPMC prepared from separate omental specimens. B. Dose effect of TNFa (;
0.1 to 1000 pg/mi) on the release of IL-6 from HPMC in the absence and in the presence of a neutralizing dose (sufficient to inhibit 100 pg/mi IL-I /3)
of monoclonal anti-human TNFa (•). Data represent (mean SCM) five separate experiments with HPMC prepared from separate omental
specimens.
Molecular weight (kD)
106
80.0
49.5
32.5
27.5
18.5
TNF-a lL-13 Control rh IL-6 MW Stds
Fig. 4. Western blot analysis of concentrated HPMC 18 hour supernatants and recombinant IL-6 using polyclonal sheep anti-human IL-6
antibody. HPMC were either unstimulated or stimulated with IL-lf3 (1000 pg/mI) or TNFa (1000 pg/mi). Data are presented from a single
representative experiment of three performed with HPMC prepared from separate omental specimens.
Discussion HPMC to synthesize IL-6 was confirmed by PCR analysis of
HPMC mRNA transcripts using specific IL-6 oligonucleotide
The present study demonstrates for the first time that non- primers, which demonstrated a 465 base pair single band of
proliferating HPMC express specific IL-6 mRNA and synthe- complementary DNA with a maximal induction between three
size immunoreactive and bioactive IL-6. The capacity of and 12 hours following IL-1$ or TNFa stimulation. Western
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IL-6 (465 bp)
Cyclophillin (326 bp)
Primers
Time, hours
I I I I I
C 3 6 12 24
.. IL-6 (465 bp)
Cyclophiflin (326 bp)
*— Primers
Fig. 5. PCR amplification of HPMC mRNA.
HPMC were either unstimulated (24 hr,
control lane) or stimulated for the time points
indicated with (A) IL-1/3 (1000 pg/mi) or (B)
TNFa (1000 pg/mi). The data presented as a
negative of the ethydium bromide stained gel
are from a single representative experiment of
three performed with mRNA from separate
HPMC preparations and is compared to the
cyclophillin (housekeeping gene) transcript
amplified from the same mRNA. (C)
Densitometric scanning of the negatives of A
and B. The data presented are the mean ratio
(O.D. IL-6/O.D. cyclophilin) of three separate
experiments with HPMC from different
donors. Symbols are: () IL-l; (•) TNFa.
blot analysis of concentrated HPMC supernatants using specific
anti-human IL-6 antibody identified immunoreactive bands at
approximately 23 and 28 Kd in cytokine treated HPMC, these
are of similar molecular mass to those demonstrable in control
and stimulated monocyte supernatants and to those previously
described for IL-6 in other cell types [23]. The cultured cells
were pure mesothelial cells as assessed morphologically (light
and electron microscopy), by the uniform positive immunoflu-
orescent staining for cytokeratins 8 and 18 and lack of staining
for factor VIII related antigen [3]. It has been suggested that
cells derived from digestion of omental tissue might be micro-
vascular endothelial cells; recent evidence, however, suggests
that these cells are in fact are of mesothelial and not endothelial
origin [24—26]. The possibility of contamination of mesothelial
cell culture by adherent macrophages was excluded by the fact
that these cells do not usually survive passage and by the lack
of Ia antigen, Fc receptor expression in all cell cultures exam-
ined.
The secretion of IL-6 protein from HPMC was time depen-
dent and occurred in a constitutive manner. Previous studies
have established that both IL-1f3 and TNFa are potent and
specific inducers of HPMC prostaglandin production [4J. In
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Fig. 6. A. PCR amplification of reverse transcribed HPMC RNA. The RNA was extracted, reverse transcribed and PCR amplified for IL-6 and
a-actin as described in methods and materials. Data presented are from a negative of the ethydium bromide stained gel from a single representative
of three performed. Cells were treated for 6 hours with control medium (lane B), interleukin-1f3 (1000 pg/ml) (lane C) or TNFa (1000 pg/ml) (lane
D). The products were subsequently electrophoresed, stained with ethydium bromide, photographed and compared to DNA standards (lane A).
In addition the specificity of the reaction was confirmed in tubes where no cDNA was present (lane E). B. Densitometric scanning of the negative
of A. The data presented are the mean ratio (O.D. IL-6/O.D. a-actin) of three separate RT/PCR experiments with HPMC from separate donors.
keeping with this specific stimulatory activity, both IL-1f3 and
TNFa induced a time and dose dependent secretion of IL-6
from HPMC. That this effect was cytokine specific was dem-
onstrated in co-incubation experiments utilizing specific anti-
IL-113 and anti-TNFa antibodies. Under these conditions IL-1f3
and TNFa triggered IL-6 synthesis could be inhibited following
incubation with the relevant antibody. Incubation of HPMC
with combined doses of IL- 1/3 and TNFa resulted in additive
increases in IL-6 generation. Western blot analysis of IL- 1/3 and
TNFa stimulated HPMC supernatants confirmed the presence
of increased levels of immunoreactive IL-6.
Goldman et al [161 have recently demonstrated low IL-6
levels in uninfected peritoneal dialysis effluent which are dra-
matically elevated during episodes of Staphylococcal peritoni-
tis. The authors suggest that the cellular source of this increased
IL-6 secretion are the activated peritoneal macrophages which
migrate into the peritoneal cavity during peritonitis. The poten-
tial of HPMC to synthesize IL-6 in response to the pro-
inflammatory cytokines IL-lf3 and TNFa suggests, however,
that the observed rise in intraperitoneal IL-6 occurring during
CAPD peritonitis might, at least in part, be of mesothelial
origin.
The precise function of high intra-peritoneal IL-6 levels is, as
yet, unknown, although recent evidence suggests that its secre-
tion may be an anti- rather than pro-inflammatory event. This
proposal is supported by the finding that IL-6 has the potential
to suppress the expression of mRNA for other cytokines
(IL-la/fl and TNFa) [27, 28]. It is, therefore, tempting to
speculate that increased intraperitoneal levels of IL-6 may
serve as a negative feedback signal for the production of IL- 1
and TNFa from activated peritoneal macrophages, thus partic-
ipating in controlling the inflammatory response in the perito-
neal cavity.
The present findings suggest that in the clinical setting of
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CAPD the peritoneal membrane not only serves as the perme-
bility barrier through which ultrafiltration occurs, but might
also be directly involved in a cytokine network within the
inflamed peritoneum, via its secretion of IL-6.
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